Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | PI4KA | P42356 | 2/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18819883 | 0.79 | PDPK1 (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL20200208 | 0.76 | CSNK2A1 (0.41) | XDHLRRK2PDPK1CSNK2A1CSNK2A2 | |
| SCHEMBL31315058 | 0.76 | CSNK2A1 (0.41) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL17253699 | 0.76 | CSNK2A1 (0.41) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL18072147 | 0.76 | NOS3 (0.38) | NOS3NOS1NOS2PI4KAPI4K2B | |
| SCHEMBL6876629 | 0.73 | PARP1 (0.42) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL6879058 | 0.73 | PDPK1 (0.44) | PDPK1CSNK2A1CSNK2A2MEN1RAB9A | |
| SCHEMBL4214823 | 0.73 | CDK1 (0.35) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL19227912 | 0.72 | PI4KA (0.35) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL17090668 | 0.71 | PDPK1 (0.44) | PDPK1CSNK2A1CSNK2A2MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | NOS3 368/4885NOS1 326/4885NOS2 309/4885 |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | NOS3 417/4885NOS1 427/4885NOS2 354/4885 |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | NOS3 368/4885NOS1 326/4885NOS2 309/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | NOS3 1526/4885NOS1 3061/4885NOS2 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.